Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity

Author： Simmons Andrew   Moskalenko Marina   Creson Jennifer   Fang Jianmin   Yi Saili   VanRoey Melinda   Allison James   Jooss Karin  

Publisher： Springer Publishing Company

ISSN： 0340-7004

Source： Cancer Immunology, Immunotherapy, Vol.57, Iss.8, 2008-08, pp. : 1263-1270

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells

By                    

Oncology Reports, Vol. 33, Iss. 6, 2015-01 ,pp. : 2947-2953

Spandidos Publications

Access to resources Recommend Favorite

Anti-CTLA4 Monoclonal Antibody Ipilimumab in the Treatment of Metastatic Melanoma: Recent Findings

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 3, Iss. 2, 2008-06 ,pp. : 105-113

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma

By Storm Phillip   Renard Violette   Moriarity John   Tyler Betty   Wilentz Robb   Brem Henry   Weingart Jon  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 361-367

Springer Publishing Company

Access to resources Recommend Favorite

Systemic Delivery of Nanoformulations of Anti-cancer Drugs with Therapeutic Potency in Animal Models of Cancer

By  

Current Cancer Therapy Reviews, Vol. 12, Iss. 3, 2017-02 ,pp. : 204-220

Bentham Science Publishers

Access to resources Recommend Favorite

CTLA‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

By  

Cancer Medicine, Vol. 4, Iss. 5, 2015-05 ,pp. : 661-672

John Wiley & Sons Inc

Access to resources Recommend Favorite